Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Change in Receivables (2022 - 2025)

Mirum Pharmaceuticals (MIRM) has 4 years of Change in Receivables data on record, last reported at $19.0 million in Q4 2025.

  • For Q4 2025, Change in Receivables rose 74.96% year-over-year to $19.0 million; the TTM value through Dec 2025 reached $48.1 million, up 320.58%, while the annual FY2025 figure was $48.1 million, 320.58% up from the prior year.
  • Change in Receivables reached $19.0 million in Q4 2025 per MIRM's latest filing, up from $3.1 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $20.1 million in Q4 2023 and bottomed at -$13.0 million in Q1 2024.
  • Average Change in Receivables over 4 years is $7.8 million, with a median of $7.9 million recorded in 2022.
  • Peak YoY movement for Change in Receivables: skyrocketed 432.94% in 2023, then plummeted 2044.38% in 2024.
  • A 4-year view of Change in Receivables shows it stood at $7.7 million in 2022, then soared by 162.95% to $20.1 million in 2023, then plummeted by 46.04% to $10.9 million in 2024, then surged by 74.96% to $19.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $19.0 million in Q4 2025, $3.1 million in Q3 2025, and $9.1 million in Q2 2025.